Glucosa B. Braun

Glucosa B. Braun is an intravenous solution that contains glucose monohydrate as its sole active ingredient. It is supplied as a sterile parenteral carbohydrate solution for infusion, without a specified concentration in the public data. The product is marketed in the European Union and is classified as a prescription‑only medication for use in clinical settings such as hospitals, surgical suites, and intensive care units.

Glucosa B. Braun is indicated for several clinical situations where rapid provision of carbohydrate calories and fluid balance is required.

- Treatment of hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens for patients unable to receive enteral feeding. - Fluid and electrolyte replacement in peri‑operative or critical‑care settings. - Source of energy during surgery, trauma care, or prolonged fasting. - Dilution medium for certain intravenous drug preparations when compatible.

When administered intravenously, Glucosa B. Braun may be associated with a range of adverse reactions, most of which are related to its osmolarity or glucose load.

Common: - Transient hyperglycemia, especially in patients with impaired glucose tolerance. - Local irritation or pain at the infusion site. - Mild electrolyte shifts such as mild hyponatremia. - Nausea or vomiting if infused rapidly.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Fluid overload causing pulmonary edema in susceptible patients. - Hypersensitivity reactions, including rash or anaphylaxis. - Hyperosmolar hyperglycemic state in diabetic individuals.

Clinicians should observe specific precautions when prescribing Glucosa B. Braun to minimize risks and ensure appropriate therapeutic benefit.

- Verify blood glucose level before and during infusion to avoid excessive hyperglycemia. - Assess fluid status and cardiac function to prevent volume overload. - Adjust dose in patients with renal or hepatic impairment. - Use caution in diabetic patients and those receiving insulin therapy. - Monitor electrolytes, particularly sodium and potassium, during prolonged administration. - Avoid rapid infusion rates that exceed recommended limits.

Glucosa B. Braun can interact with other medications or clinical conditions; awareness of these interactions helps maintain safety.

Avoid: - Concurrent administration with high‑dose insulin without glucose monitoring. - Co‑infusion with potassium chloride solutions that may precipitate. - Use with other hypertonic carbohydrate solutions that could exacerbate hyperglycemia.

Use with caution: - Simultaneous IV administration of diuretics, which may amplify fluid shifts. - Concurrent use of corticosteroids that increase glucose production. - Patients receiving total parenteral nutrition containing additional dextrose sources.